NBTXR-3 is under clinical development by Nanobiotix and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NBTXR-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NBTXR-3 overview

NBTXR-3 is under development for the treatment of head and neck cancer squamous cell carcinoma, soft tissue sarcoma, esophageal cancer, pancreatic ductal adenocarcinoma, esophageal adenocarcinoma, pancreatic cancer, hepatocellular carcinoma, melanoma, renal cell carcinoma, transitional cell cancer (urothelial cell cancer), cervical cancer, triple-negative breast cancer (TNBC), metastatic liver cancer, non-small cell lung cancer, squamous cell carcinoma (SCC) of the oral cavity or oropharynx, laryngeal cancer and hypopharyngeal cancer and solid tumor. It is administered through intratumoral route. The therapeutic candidate is composed of functionalized hafnium oxide nanoparticles. It was also under development for rectal cancer. The drug candidate is a radiation sensitizer.

Nanobiotix overview

Nanobiotix designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, esophageal, pancreatic, liver, rectal, prostate, head and neck cancers; non-small cell lung cancer (NSCLC); recurrent head and neck, lung and liver metastasis cancers. Its product candidate is a first-in-class radiohancer composed of hafnium oxide nanoparticles and is activated by radiation therapy to destroy tumors. The company markets NBTXR3 under the brand name Hensify in Europe to treat patients with soft tissue sarcoma. It operates in the US, Spain and Germany. Nanobiotix is headquartered in Paris, Ile-de-France, France.

For a complete picture of NBTXR-3’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.